Sign in or create an account to add this stock to your watchlist.
About Crispr Therapeutics (NASDAQ:CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-61-228-7800
Debt
Debt-to-Equity RatioN/A
Current Ratio24.42
Quick Ratio24.42
Price-To-Earnings
Trailing P/E Ratio-40.90
Forward P/E Ratio-26.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$41 million
Price / Sales80.50
Cash FlowN/A
Price / CashN/A
Book Value$6.15 per share
Price / Book11.37
Profitability
EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-189.60%
Return on Equity-35.18%
Return on Assets-24.39%
Miscellaneous
Employees127
Outstanding Shares47,190,000
Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
What is Crispr Therapeutics' stock symbol?
Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
How were Crispr Therapeutics' earnings last quarter?
Crispr Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.05. The firm earned $1.36 million during the quarter, compared to analyst estimates of $3.64 million. Crispr Therapeutics had a negative return on equity of 35.18% and a negative net margin of 189.60%. The business's quarterly revenue was down 49.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.54) earnings per share. View Crispr Therapeutics' Earnings History.
When is Crispr Therapeutics' next earnings date?
What price target have analysts set for CRSP?
9 brokers have issued 12 month target prices for Crispr Therapeutics' stock. Their predictions range from $51.00 to $86.00. On average, they expect Crispr Therapeutics' share price to reach $65.1714 in the next year. View Analyst Ratings for Crispr Therapeutics.
What are Wall Street analysts saying about Crispr Therapeutics stock?
Here are some recent quotes from research analysts about Crispr Therapeutics stock:
- 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (5/23/2018)
- 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
- 3. Chardan Capital analysts commented, "We calculated the CRISPR sector enterprise value (EV) by discounting Chardan target sector EVs of companies in the AAV (assumed 3 years ahead) and small RNA (assumed 3 years ahead) gene therapy sectors; we applied a discount rate of 20%, which we believe is reasonable for preclinical biotech firms. Giving CRSP a CRISPR sector valuation distribution of 15% of the calculated CRISPR sector EV (based on our view of the firm’s relative IP weakness balanced by potential first entry of a CRISPR therapy into the clinic) and adding $272.3 mm in cash, we project a CRSP market cap range of $866 mm-$901 mm." (8/14/2017)
Who are some of Crispr Therapeutics' key competitors?
Some companies that are related to Crispr Therapeutics include NOVOZYMES A/S/S (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Repligen (RGEN) and Denali Therapeutics (DNLI).
Who are Crispr Therapeutics' key executives?
Crispr Therapeutics' management team includes the folowing people:
- Dr. Rodger Novak, Founder & Chairman (Age 51)
- Mr. Marc A. Becker, Former CFO & Sr. VP (Age 46)
- Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
- Dr. N. Anthony Coles Jr., Sr. Advisor (Age 58)
- Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)
When did Crispr Therapeutics IPO?
(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.
Has Crispr Therapeutics been receiving favorable news coverage?
Media headlines about CRSP stock have trended positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Crispr Therapeutics earned a news sentiment score of 0.46 on Accern's scale. They also gave headlines about the company an impact score of 46.14 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Crispr Therapeutics' major shareholders?
Crispr Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (9.77%), NEA Management Company LLC (7.39%), Abingworth LLP (4.00%), Franklin Resources Inc. (1.51%), Farallon Capital Management LLC (1.37%) and BlackRock Inc. (1.21%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Simeon George, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Institutional Ownership Trends for Crispr Therapeutics.
Which major investors are selling Crispr Therapeutics stock?
CRSP stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Farallon Capital Management LLC, Franklin Resources Inc., Abingworth LLP, GSA Capital Partners LLP, Artal Group S.A., Trexquant Investment LP and A.R.T. Advisors LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Insider Buying and Selling for Crispr Therapeutics.
Which major investors are buying Crispr Therapeutics stock?
CRSP stock was purchased by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Wells Fargo & Company MN, NEA Management Company LLC, First Allied Advisory Services Inc., UBS Group AG, Victory Capital Management Inc., CIBC World Markets Inc. and Hilltop Holdings Inc.. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer, Corp /De/ Celgene and Simeon George. View Insider Buying and Selling for Crispr Therapeutics.
How do I buy shares of Crispr Therapeutics?
Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Crispr Therapeutics' stock price today?
One share of CRSP stock can currently be purchased for approximately $69.94.
How big of a company is Crispr Therapeutics?
Crispr Therapeutics has a market capitalization of $3.30 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Crispr Therapeutics employs 127 workers across the globe.
How can I contact Crispr Therapeutics?
Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.
MarketBeat Community Rating for Crispr Therapeutics (CRSP)
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Crispr Therapeutics (NASDAQ:CRSP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Crispr Therapeutics in the last 12 months. Their average twelve-month price target is $65.1714, suggesting that the stock has a possible downside of 6.82%. The high price target for CRSP is $86.00 and the low price target for CRSP is $51.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $65.1714 | $63.95 | $22.8125 | $22.3750 |
| Price Target Upside: | 6.82% downside | 49.87% upside | 32.41% downside | 28.22% upside |
Crispr Therapeutics (NASDAQ:CRSP) Consensus Price Target History
Crispr Therapeutics (NASDAQ:CRSP) Analyst Ratings History
Show:
(Data available from 5/28/2016 forward)
Crispr Therapeutics (NASDAQ:CRSP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Crispr Therapeutics (NASDAQ CRSP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 37.70%
Institutional Ownership Percentage: 39.27%
Crispr Therapeutics (NASDAQ CRSP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2018 | Rodger Novak | President | Sell | 75,000 | $60.00 | $4,500,000.00 | 1,183,247 |  |
| 5/14/2018 | Kurt Von Emster | Director | Sell | 650,000 | $54.39 | $35,353,500.00 | 5,629 | |
| 5/11/2018 | Kurt Von Emster | Director | Sell | 250,000 | $52.84 | $13,210,000.00 | | |
| 5/8/2018 | Bradley J Phd Bolzon | Director | Sell | 128,950 | $50.39 | $6,497,790.50 | 37,645 | |
| 4/30/2018 | Bradley J Phd Bolzon | Director | Sell | 30,566 | $50.29 | $1,537,164.14 | 43,986 | |
| 4/27/2018 | Thomas Woiwode | Director | Sell | 222,258 | $50.11 | $11,137,348.38 | | |
| 4/24/2018 | Versant Venture Capital V, L.P | Major Shareholder | Sell | 22,841 | $50.99 | $1,164,662.59 | | |
| 4/23/2018 | Bradley J Phd Bolzon | Director | Sell | 101,994 | $50.68 | $5,169,055.92 | 43,986 | |
| 1/16/2018 | Tyler Dylan-Hyde | Insider | Sell | 66,000 | $28.03 | $1,849,980.00 | 25,204 | |
| 1/5/2018 | Aktiengesellschaft Bayer | Major Shareholder | Buy | 527,472 | $22.75 | $11,999,988.00 | | |
| 1/5/2018 | Kurt Von Emster | Director | Sell | 92,337 | $26.96 | $2,489,405.52 | | |
| 1/2/2018 | Kurt Von Emster | Director | Sell | 37,754 | $26.76 | $1,010,297.04 | | |
| 1/2/2018 | Tyler Dylan-Hyde | Insider | Sell | 38,000 | $21.64 | $822,320.00 | 70,204 | |
| 12/29/2017 | Tyler Dylan-Hyde | Insider | Sell | 31,000 | $22.72 | $704,320.00 | | |
| 12/28/2017 | Tyler Dylan-Hyde | Insider | Sell | 700 | $21.75 | $15,225.00 | 115,904 | |
| 12/22/2017 | Thomas Woiwode | Director | Sell | 3,059 | $20.29 | $62,067.11 | 4,959 | |
| 12/22/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $20.55 | $308,250.00 | 115,204 | |
| 12/15/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $18.90 | $283,500.00 | 130,204 | |
| 12/4/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 1,112,446 | $18.98 | $21,114,225.08 | | |
| 12/1/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 87,991 | $19.10 | $1,680,628.10 | | |
| 11/29/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 4,263 | $19.25 | $82,062.75 | | |
| 11/27/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 27,990 | $19.75 | $552,802.50 | | |
| 11/27/2017 | Thomas Woiwode | Director | Sell | 200 | $20.24 | $4,048.00 | 8,218 | |
| 11/24/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 26,010 | $20.00 | $520,200.00 | | |
| 11/24/2017 | Thomas Woiwode | Director | Sell | 1,700 | $20.21 | $34,357.00 | 8,218 | |
| 11/22/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 256,000 | $19.76 | $5,058,560.00 | | |
| 11/20/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 158,718 | $19.02 | $3,018,816.36 | | |
| 11/17/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 51,282 | $18.44 | $945,640.08 | | |
| 11/15/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 15,000 | $17.67 | $265,050.00 | | |
| 11/13/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 65,093 | $17.76 | $1,156,051.68 | | |
| 11/10/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 10,000 | $17.28 | $172,800.00 | | |
| 11/8/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 16,875 | $18.06 | $304,762.50 | | |
| 11/6/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 79,327 | $18.89 | $1,498,487.03 | | |
| 11/3/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 22,759 | $19.10 | $434,696.90 | | |
| 9/5/2017 | Rodger Novak | CEO | Sell | 18,470 | $20.76 | $383,437.20 | 1,148,007 | |
| 8/30/2017 | Rodger Novak | CEO | Sell | 75,795 | $20.25 | $1,534,848.75 | 1,232,697 | |
| 8/30/2017 | Samarth Kulkarni | Insider | Sell | 27,154 | $20.08 | $545,252.32 | 110,893 | |
| 8/28/2017 | Kurt Von Emster | Director | Sell | 88,011 | $19.79 | $1,741,737.69 | | |
| 8/25/2017 | Kurt Von Emster | Director | Sell | 22,781 | $19.42 | $442,407.02 | | |
| 8/23/2017 | Kurt Von Emster | Director | Sell | 17,989 | $18.53 | $333,336.17 | | |
| 8/21/2017 | Kurt Von Emster | Director | Sell | 3,150 | $18.52 | $58,338.00 | | |
| 8/17/2017 | Kurt Von Emster | Director | Sell | 34,141 | $19.06 | $650,727.46 | | |
| 8/15/2017 | Kurt Von Emster | Director | Sell | 55,569 | $19.59 | $1,088,596.71 | | |
| 8/8/2017 | Kurt Von Emster | Director | Sell | 35,473 | $18.63 | $660,861.99 | | |
| 8/8/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $18.57 | $278,550.00 | 167,727 | |
| 8/4/2017 | Kurt Von Emster | Director | Sell | 50,477 | $17.81 | $898,995.37 | | |
| 8/1/2017 | Kurt Von Emster | Director | Sell | 5,512 | $17.51 | $96,515.12 | | |
| 7/28/2017 | Kurt Von Emster | Director | Sell | 41,312 | $17.63 | $728,330.56 | | |
| 7/26/2017 | Kurt Von Emster | Director | Sell | 32,930 | $17.60 | $579,568.00 | | |
| 7/14/2017 | Kurt Von Emster | Director | Sell | 69,859 | $16.84 | $1,176,425.56 | | |
| 7/12/2017 | Kurt Von Emster | Director | Sell | 31,992 | $16.56 | $529,787.52 | | |
| 7/5/2017 | Kurt Von Emster | Director | Sell | 4,254 | $16.26 | $69,170.04 | | |
| 6/29/2017 | Kurt Von Emster | Director | Sell | 43,202 | $16.90 | $730,113.80 | | |
| 6/27/2017 | Kurt Von Emster | Director | Sell | 81,435 | $17.08 | $1,390,909.80 | | |
| 6/23/2017 | Kurt Von Emster | Director | Sell | 32,368 | $16.23 | $525,332.64 | | |
| 6/22/2017 | Rodger Novak | CEO | Sell | 10,825 | $15.37 | $166,380.25 | 1,225,830 | |
| 6/21/2017 | Rodger Novak | CEO | Sell | 30,222 | $15.01 | $453,632.22 | 1,230,397 | |
| 6/9/2017 | Rodger Novak | CEO | Sell | 5,303 | $15.02 | $79,651.06 | 1,219,208 | |
| 5/30/2017 | Rodger Novak | CEO | Sell | 3,650 | $15.02 | $54,823.00 | 1,218,655 | |
| 5/17/2017 | Rodger Novak | CEO | Sell | 50,000 | $16.26 | $813,000.00 | 1,239,082 | |
| 5/5/2017 | Rodger Novak | CEO | Sell | 616 | $16.92 | $10,422.72 | 1,215,621 | |
| 5/4/2017 | Rodger Novak | CEO | Sell | 49,384 | $16.30 | $804,959.20 | 1,230,929 | |
| 4/28/2017 | Tyler Dylan-Hyde | Insider | Sell | 21,639 | $16.78 | $363,102.42 | 180,495 | |
| 4/27/2017 | Samarth Kulkarni | Insider | Sell | 5,481 | $16.76 | $91,861.56 | 137,322 | |
| 4/25/2017 | Samarth Kulkarni | Insider | Sell | 11,615 | $16.78 | $194,899.70 | 137,047 | |
| 4/20/2017 | Rodger Novak | CEO | Sell | 50,000 | $17.88 | $894,000.00 | 1,262,711 | |
| 4/20/2017 | Tyler Dylan-Hyde | Insider | Sell | 10,177 | $17.71 | $180,234.67 | 200,274 | |
| 10/24/2016 | Corp /De/ Celgene | Major Shareholder | Buy | 800,150 | $14.00 | $11,202,100.00 | | |
| 10/24/2016 | Simeon George | Director | Buy | 66,500 | $14.00 | $931,000.00 | | |
(Data available from 1/1/2013 forward)
Crispr Therapeutics (NASDAQ CRSP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Rounds Report: Crispr Rallied While The FDA Approved Lumivascular
seekingalpha.com - May 25 at 9:21 AM |
 | Is Genome Editing the Next Biotech Breakthrough?
www.zacks.com - May 24 at 4:31 PM |
 | Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Align Technology
finance.yahoo.com - May 24 at 9:29 AM |
 | Insider Selling: CRISPR Therapeutics (CRSP) President Sells 75,000 Shares of Stock
www.americanbankingnews.com - May 21 at 7:16 PM |
| CRISPR Therapeutics (CRSP) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 18 at 4:36 PM |
| MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus
finance.yahoo.com - May 18 at 4:35 PM |
| Why Wall Street Analysts Are Mostly Positive on CRISPR
finance.yahoo.com - May 18 at 4:35 PM |
| CRISPR Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle Royale
seekingalpha.com - May 17 at 4:49 PM |
| Insider Selling: CRISPR Therapeutics (CRSP) Director Sells 250,000 Shares of Stock
www.americanbankingnews.com - May 15 at 10:12 PM |
| CRISPR Therapeutics (CRSP) Director Sells $35,353,500.00 in Stock
www.americanbankingnews.com - May 15 at 10:12 PM |
| CRISPR Therapeutics (CRSP) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 15 at 1:31 PM |
| CRISPR Therapeutics (CRSP) Price Target Raised to $72.50 at Chardan Capital
www.americanbankingnews.com - May 15 at 1:19 PM |
| CRISPR Therapeutics (CRSP) Downgraded by TheStreet to "D+"
www.americanbankingnews.com - May 15 at 1:06 PM |
| CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
finance.yahoo.com - May 15 at 9:59 AM |
| $1.47 Million in Sales Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - May 14 at 4:25 AM |
| Analysts Anticipate CRISPR Therapeutics (CRSP) Will Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - May 12 at 10:49 AM |
| CRISPR Therapeutics Q1 2018 Review
seekingalpha.com - May 12 at 10:08 AM |
| CRISPR Therapeutics (CRSP) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 11 at 9:05 PM |
 | CRISPR: 3 Strong Buy Biotechs Trying To Edit Our Genes
www.nasdaq.com - May 11 at 10:22 AM |
| CRISPR Therapeutics (CRSP) Forecasted to Earn Q2 2018 Earnings of ($0.71) Per Share
www.americanbankingnews.com - May 11 at 9:05 AM |
| Oppenheimer Comments on CRISPR Therapeutics' Q2 2018 Earnings (CRSP)
www.americanbankingnews.com - May 11 at 9:05 AM |
| Q1 2018 EPS Estimates for CRISPR Therapeutics Decreased by Analyst (CRSP)
www.americanbankingnews.com - May 10 at 6:15 AM |
| CRISPR Therapeutics (CRSP) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - May 9 at 7:57 PM |
| CRISPR Therapeutics (CRSP) Director Bradley J. Phd Bolzon Sells 128,950 Shares
www.americanbankingnews.com - May 9 at 7:15 PM |
| Is CRISPR Therapeutics AG’s (NASDAQ:CRSP) Liquidity Good Enough?
finance.yahoo.com - May 9 at 4:32 PM |
 | Global Market and Potential for CRISPR/Cas9 Gene Editing to 2023
globenewswire.com - May 9 at 9:30 AM |
 | BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62
www.reuters.com - May 9 at 9:30 AM |
| CRISPR Therapeutics (CRSP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 9 at 1:22 AM |
| CRISPR Therapeutics beats by $0.05, misses on revenue
seekingalpha.com - May 8 at 9:22 AM |
| CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 9:22 AM |
| Intellia Therapeutics - Buy The Pullback?
seekingalpha.com - May 7 at 4:38 PM |
| My Favorite Investment For The Coming Biotech Bull Market (Avisol Capital Partners)
seekingalpha.com - May 7 at 4:38 PM |
 | This Rapidly Growing Biotech Could Be The Game Changing Stock Of 2018
www.baystreet.ca - May 4 at 9:22 AM |
 | Jim Cramer Advises His Viewers On Skyworks And Crispr Therapeutics
www.benzinga.com - May 3 at 4:25 PM |
| CRISPR Therapeutics to Participate in May Investor Conferences
finance.yahoo.com - May 3 at 4:25 PM |
| CRISPR Therapeutics (CRSP) Director Sells $1,537,164.14 in Stock
www.americanbankingnews.com - May 2 at 7:21 PM |
 | Update On Crispr And Sorrento
www.forbes.com - May 2 at 4:32 PM |
| CRISPR Therapeutics (CRSP) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 2 at 7:18 AM |
| CRISPR Therapeutics (CRSP) Director Sells $11,137,348.38 in Stock
www.americanbankingnews.com - April 30 at 10:10 PM |
| CRISPR/Cas9 gene editors in negative territory as appellate-level patent dispute begins
seekingalpha.com - April 30 at 4:27 PM |
| Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Merck & Co.
finance.yahoo.com - April 30 at 9:39 AM |
| Exclusive: Gene editing pioneer Feng Zhang launches new startup in Cambridge
finance.yahoo.com - April 27 at 4:28 PM |
| CRISPR Therapeutics (CRSP) Major Shareholder Versant Venture Capital V, L.P Sells 22,841 Shares
www.americanbankingnews.com - April 26 at 7:12 PM |
| $2.97 Million in Sales Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - April 26 at 2:00 AM |
| CRISPR Therapeutics (CRSP) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 25 at 12:26 AM |
| CRISPR Therapeutics (CRSP) Director Sells $5,169,055.92 in Stock
www.americanbankingnews.com - April 24 at 10:22 PM |
| -$0.67 Earnings Per Share Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - April 24 at 9:16 PM |
| Geron Corporation: The Clock Is Ticking
finance.yahoo.com - April 23 at 4:26 PM |
| What Are Analysts Expecting From CRISPR Therapeutics AG (NASDAQ:CRSP) Over The Next Few Years?
finance.yahoo.com - April 23 at 9:10 AM |
| Big Week in Tech for Amazon, Alphabet and Microsoft
finance.yahoo.com - April 22 at 5:17 PM |
Crispr Therapeutics (NASDAQ:CRSP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Crispr Therapeutics (NASDAQ:CRSP) Income Statement, Balance Sheet and Cash Flow Statement
Crispr Therapeutics (NASDAQ CRSP) Stock Chart for Monday, May, 28, 2018
Loading chart…
